Peritonitis from <i>Leclercia adecarboxylata</i>: An emerging pathogen

Adapa, Sreedhar; Konala, Venu Madhav; Nawaz, Faiza; Javed, Tariq; Dhingra, Hemant; Gutierrez, Irene A.; Ramirez, Magda L.

doi:10.1002/ccr3.2094

Cited by 13 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the number of studies on the clinical role of L. adecarboxylata as an opportunistic pathogen is increasing, the frequency of reports is currently still too small to estimate the route of transmission and significance of this pathogen properly [25]. It has been suggested that this microorganism has a low pathogenic potential and the virulence factors of this species have not been adequately characterized [26]. Thus, to cause infection, there has to be some kind of breach in the anatomical continuity of the tissue, an underlying disease or immunosuppression: e.g.…”

Section: Discussionmentioning

confidence: 99%

Leclercia adecarboxylata as an emerging pathogen in human infections: a 13-year retrospective analysis in Southern Hungary

Gajdács

Ábrók

Lázár

et al. 2020

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: The clinical role of Leclercia adecarboxylata as an opportunistic pathogen in the context of human infections have been highlighted by multiple published case reports, describing these bacteria as novel or emerging pathogens. Methodology: The study included L. adecarboxylata isolates and laboratory data collected, corresponding to a 13-year time period (between 1 January 2005 and 31 December 2017). Presumptively identified L. adecarboxylata isolates were re-identified using VITEK 2 Compact ID/AST and MALDI-TOF MS analysis. Results: n = 34 isolates were verified by VITEK 2 system and MALDI-TOF. The fosfomycin-agar and CPS Elite agar were effective in the phenotypic differentiation of the isolates. N = 18 (52.9%) of L. adecarboxylata was considered as clinically significant pathogens (based on the clinical signs and symptoms), while n = 16 (47.1%) were considered as contaminants. These pathogens were isolated from wound/abscess samples (n = 9), urine samples (n = 6) and blood cultures (n = 3). 31 out of 34 isolates (91.2%) were pan-sensitive (i.e. wild type) to the tested antibiotics. The median age of affected patients was 57 years (range: 12-80 years), 11 out of 18 patients (61.1%) presented with underlying immunosuppression at the time of isolation. Conclusions: Based on the finding of this study, the actual (published) frequency of L. adecarboxylata infections needs to be re-evaluated as the risk of misidentification (and reporting the isolate as a pan-sensitive Escherichia coli) is high. Additional reporting of cases, both from a microbiological and clinical standpoint, could help clinicians develop a better understanding of the potential of this organism as a pathogen.

show abstract

Section: Discussionmentioning

confidence: 99%

Leclercia adecarboxylata as an emerging pathogen in human infections: a 13-year retrospective analysis in Southern Hungary

Gajdács

Ábrók

Lázár

et al. 2020

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…End-stage renal disease Peritoneal fluid None Fattal and Deville [9] Premature birth Blood None Myers et al [10] Premature birth Blood None Nelson et al [11] Acute lymphoblastic leukemia Blood Staphylococcus aureus Longhurst and West [12] Leukopenia and neutropenia Blood None Sethi et al [14] Acute lymphoblastic leukemia Cellulitis None Shah et al [15] To our knowledge, the second case is the first published L. adecarboxylata UTI in a pediatric patient. L. adecarboxylata infections have been reported in the adult population after foreign body placements such as a central line or a peritoneal catheter [16,17]. Similarly, a child was infected with L. adecarboxylata during peritoneal dialysis for end-stage renal disease [9].…”

Section: Discussionmentioning

confidence: 99%

Leclercia adecarboxylata: An Emerging Pathogen Among Pediatric Infections

Keyes¹,

Johnson²,

Epelman³

et al. 2020

Cureus

View full text Add to dashboard Cite

Leclercia adecarboxylata is a gram-negative bacillus of the Enterobacteriaceae family. It is a rare human pathogen that is often acquired via wound and/or contact with aquatic environment. Although multiple cases of L. adecarboxylata infections are described in the adult population, few have been documented in pediatrics. We will present two cases of L. adecarboxylata infections in the pediatric population. The first is a case of cellulitis in an 11-year-old male patient after a penetrating wound. The second is a first-documented urinary tract infection in a 16-year-old male patient with chronic kidney disease. Both patients were successfully treated with antibiotics and surgical intervention, if necessary. These cases highlight the growing emergence of this bacterium in the pediatric population and the need to become more aware of its threat even in patients who are immunocompetent.

show abstract

“…Due to advancement in microbiology identification capabilities, there have been an increasing number of L. adecarboxylata infections diagnosed, primarily as an opportunistic pathogen. It has been hypothesized that certain cases of possible L. adecarboxylata infections may have previously been misdiagnosed as E. coli due to a lack of awareness surrounding the bacterium [ 3 ].…”

Section: Discussionmentioning

confidence: 99%

Leclercia Adecarboxylata Causing Necrotizing Fasciitis in an Immunocompetent Athlete Injecting Illicit Testosterone Supplements

Kaushik¹,

Mittal²,

Tirador³

et al. 2020

Cureus

View full text Add to dashboard Cite

Leclercia adecarboxylata (L. adecarboxylata) is an uncommon and often misdiagnosed cause of multiple infection types including skin and soft tissue, cholecystitis, and septicemia. It commonly afflicts immunocompromised hosts or individuals who experience trauma in aquatic environments. We present a case where this bacteria causes necrotizing fasciitis as a consequence of injecting street bought testosterone supplements. This patient was treated successfully with excisional debridement of the wound as well as a one week course of Linezolid and Bactrim.

show abstract

Peritonitis from Leclercia adecarboxylata: An emerging pathogen

Cited by 13 publications

References 14 publications

Leclercia adecarboxylata as an emerging pathogen in human infections: a 13-year retrospective analysis in Southern Hungary

Leclercia adecarboxylata as an emerging pathogen in human infections: a 13-year retrospective analysis in Southern Hungary

Leclercia adecarboxylata: An Emerging Pathogen Among Pediatric Infections

Leclercia Adecarboxylata Causing Necrotizing Fasciitis in an Immunocompetent Athlete Injecting Illicit Testosterone Supplements

Contact Info

Product

Resources

About